In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 10, 2018, Pages 2777-2781

  Kazmierczak, Krystyna M ^a   de Jonge, Boudewijn L M ^b,c   Stone, Gregory G ^b,c   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; COLISTIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PENICILLINASE; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; COLISTIN RESISTANCE; CONTROLLED STUDY; CZECH REPUBLIC; DRUG POTENCY; GREECE; IN VITRO STUDY; MIC90; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; ROMANIA; RUSSIAN FEDERATION; DNA SEQUENCE; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; EPIDEMIOLOGICAL MONITORING; EUROPE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; DRUG COMBINATIONS; EPIDEMIOLOGICAL MONITORING; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEQUENCE ANALYSIS, DNA;

EID: 85059895239     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky267     Document Type: Article

References (19)

1. WHO. Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis. Geneva, Switzerland: WHO, 2017. http://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf?ua"1.
2. ECDC. Antimicrobial Resistance Surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC, 2017. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf.
3. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634–40.
4. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582–610.
5. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 4783–8.
6. Torrens G, Cabot G, Ocampo-Sosa AA et al. Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant b-lactam resistance mechanisms. Antimicrob Agents Chemother 2016; 60: 6407–10.
7. Cabot G, Ocampo-Sosa AA, Tubau F et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011; 55: 1906–11.
8. Riera E, Cabot G, Mulet X et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem, and doripenem. J Antimicrob Chemother 2011; 66: 2022–7.
9. Castanheira M, Deshpande LM, Costello A et al. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–2011 in 14 European and Mediterranean countries. J Antimicrob Chemother 2014; 69: 1804–14.
10. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390–4.
11. Li H, Estabrook M, Jacoby GA et al. In vitro susceptibility of characterized b-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 2015; 59: 1789–93.
12. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime ! NXL104 against Pseudomonas aeruginosa and other non-fer-menters. J Antimicrob Chemother 2010; 65: 2376–81.
13. Lahiri SD, Alm RA. Identification of novel VEB b-lactamase enzymes and their impact on avibactam inhibition. Antimicrob Agents Chemother 2016; 60: 3183–6.
14. Karlowsky JA, Biedenbach DJ, Kazmierczak KM et al. Activity of ceftazidime-avibactam against extended-spectrum- and AmpC b-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014. Antimicrob Agents Chemother 2016; 60: 2849–57.
15. Winkler ML, Papp-Wallace KM, Hujer AM et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2015; 59: 1020–9.
16. Buehrle DJ, Shields RK, Chen L et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 2016; 60: 3227–31.
17. Lahiri SD, Walkup GK, Whiteaker JD et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 2015; 70: 1650–8.
18. Lahiri SD, Johnstone MR, Ross PL et al. Avibactam and class C b-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 2014; 58: 5704–13.
19. AstraZeneca Pharmaceuticals. Zavicefta Package Insert, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf.